TY - JOUR
T1 - Left Main Percutaneous Coronary Revascularization
AU - Almoghairi, Abdulrahman
AU - Al-Asiri, Nayef
AU - Aljohani, Khalid
AU - AlSaleh, Ayman
AU - Alqahtani, Nasser G.
AU - Alasmary, Mohammed
AU - Alali, Rudaynah
AU - Tamam, Khaled
AU - Alasnag, Mirvat
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Radcliffe Group Ltd.
PY - 2023
Y1 - 2023
N2 - Left main (LM) coronary artery disease accounts for approximately 4–6% of all percutaneous coronary interventions (PCIs). There has been mounting evidence indicating the non-inferiority of LM PCI as a revascularization option, particularly for those with a low SYNTAX score. The EXCEL and NOBEL trials have shaped current guidelines. The European Society of Cardiology assigned a class 2a (level of evidence B) for isolated LM disease involving the shaft and ostium and a class IIb (level of evidence B) for isolated LM disease involving the bifurcation or additional two- or three-vessel disease and a SYNTAX score <32. However, data on the use of a single stent or an upfront two-stent strategy for distal LM disease are conflicting, wherein the EBC Main trial reported similar outcomes with a stepwise provisional approach and the DKCRUSH-V trial reported better outcomes with an upfront two-stent strategy using the ‘double-kissing’ crush technique. Although several studies have noted better immediate results with image-guided PCI, there are few data on outcomes in LM disease specifically. In fact, the uptake of imaging in the aforementioned landmark trials was only 40%. More importantly, the role of mechanical circulatory support (MCS) has been less well studied in LM PCI. Indiscriminate use of MCS for LM PCI has been noted in clinical practice. Trials evaluating the benefit of MCS in high-risk PCI demonstrated no benefit. This review highlights contemporary trials as they apply to current practice in LM PCI.
AB - Left main (LM) coronary artery disease accounts for approximately 4–6% of all percutaneous coronary interventions (PCIs). There has been mounting evidence indicating the non-inferiority of LM PCI as a revascularization option, particularly for those with a low SYNTAX score. The EXCEL and NOBEL trials have shaped current guidelines. The European Society of Cardiology assigned a class 2a (level of evidence B) for isolated LM disease involving the shaft and ostium and a class IIb (level of evidence B) for isolated LM disease involving the bifurcation or additional two- or three-vessel disease and a SYNTAX score <32. However, data on the use of a single stent or an upfront two-stent strategy for distal LM disease are conflicting, wherein the EBC Main trial reported similar outcomes with a stepwise provisional approach and the DKCRUSH-V trial reported better outcomes with an upfront two-stent strategy using the ‘double-kissing’ crush technique. Although several studies have noted better immediate results with image-guided PCI, there are few data on outcomes in LM disease specifically. In fact, the uptake of imaging in the aforementioned landmark trials was only 40%. More importantly, the role of mechanical circulatory support (MCS) has been less well studied in LM PCI. Indiscriminate use of MCS for LM PCI has been noted in clinical practice. Trials evaluating the benefit of MCS in high-risk PCI demonstrated no benefit. This review highlights contemporary trials as they apply to current practice in LM PCI.
KW - intracoronary imaging
KW - Left main
KW - mechanical circulatory support
KW - revascularization
UR - https://www.scopus.com/pages/publications/85169810343
U2 - 10.15420/usc.2022.24
DO - 10.15420/usc.2022.24
M3 - Review article
AN - SCOPUS:85169810343
SN - 1758-3896
VL - 17
JO - US Cardiology Review
JF - US Cardiology Review
M1 - e09
ER -